Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine (Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences) have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

COVID-19 treatments in care homes

The study included almost 30,000 highly vulnerable nursing home residents who were under-represented in previous clinical trials. In addition, more than 26,000 nursing home staff and over 60,000 healthcare workers were studied, with reductions in infections comparable to those seen in nursing home residents.

“This study confirms the great value of the ongoing vaccination programmes to reduce COVID-19 transmission and the related healthcare burden and mortality,” said Dr Carmen Cabezas, Health Secretary for Catalonia. “Our strategy to vaccinate those most at risk first has proven valuable to reduce the impact of COVID-19 on those most likely to suffer severe forms of the disease. In addition, our plan to prioritise those most exposed to the virus, including our healthcare workers, has also proven useful to keep patients and staff safe whilst they care for us.  

Dr Prieto-Alhambra, Professor of Pharmacoepidemiology at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (University of Oxford) and senior author said: “We are collaborating internationally to produce solid evidence on the risk-benefit of COVID vaccines. Linked real world data from Catalonia and other parts of the world is being used for the study of the safety of vaccines. Here, we used linked primary care, hospital, vaccine, and laboratory data from Catalonia to expand our knowledge on their effectiveness in special subpopulations. The observed effects were in line with those seen in previous clinical trials.”  

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website.

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.